A mice study demonstrated that the release of mast cell PAF could explain disseminated intravascular coagulation symptoms (thrombocytopenia, prolongation of prothrombin time and hypofibrinogenemia, and increase levels of D-dimer), since PAF antagonists could prevent these effects while intravenous PAF was able to reproduce some of the symptoms (53). The gene discussed is PCLAF; the disease is Hypofibrinogenemia.